Prosecution Insights
Last updated: April 19, 2026

Examiner: GIAMMONA, FRANCESCA FILIPPA

Tech Center 1600 • Art Units: 1637 1681

This examiner grants 36% of resolved cases

Performance Statistics

36.4%
Allow Rate
-23.6% vs TC avg
132
Total Applications
+50.9%
Interview Lift
1336
Avg Prosecution Days
Based on 66 resolved cases, 2023–2026

Rejection Statute Breakdown

8.5%
§101 Eligibility
10.3%
§102 Novelty
42.0%
§103 Obviousness
30.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18190809 SYSTEMS AND METHODS OF SEQUENCING POLYNUCLEOTIDES Final Rejection Illumina, Inc.
17197836 Nucleic Acid Sequence Analysis from Single Cells Non-Final OA Illumina, Inc.
17415326 COMPOSITIONS AND METHOD FOR SYNTHESIZING NUCLEIC ACIDS Final Rejection PRESIDENT AND FELLOWS OF HARVARD COLLEGE
17470523 COMBINED MULTIPLE-DISPLACEMENT AMPLIFICATION AND PCR IN AN EMULSION MICRODROPLET Non-Final OA The Regents of the University of California
19326091 COMPOSITIONS AND METHODS OF MAKING GENE EXPRESSION LIBRARIES Final Rejection 10x Genomics, Inc.
17271866 Methods for Generating Spatially Barcoded Arrays Non-Final OA 10x Genomics, Inc.
17342327 MICRONEEDLE-BASED RAPID ANALYTE EXTRACTION FROM PLANT AND ANIMAL TISSUES AND RELATED METHODS AND SYSTEMS Non-Final OA North Carolina State University
17421677 RAPID REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN REACTION Final Rejection Northwestern University
18027087 RANDOM INSERTION GENOME RECONSTRUCTION Final Rejection GOOGLE LLC
17621122 DNA MARKERS FOR DIFFERENTIATION OF BIOPSY SAMPLES Final Rejection The Johns Hopkins University
17294179 CRISPR SYSTEM BASED DROPLET DIAGNOSTIC SYSTEMS AND METHODS Non-Final OA THE GENERAL HOSPITAL CORPORATION
17925693 METHODS FOR DETECTION OF DONOR-DERIVED CELL-FREE DNA Final Rejection Natera, Inc.
17600789 IMPROVED LIQUID BIOPSY USING SIZE SELECTION Non-Final OA Natera, Inc.
17427394 COST-EFFECTIVE DETECTION OF LOW FREQUENCY GENETIC VARIATION Final Rejection CHILDREN'S MEDICAL CENTER CORPORATION
17441670 SIGNATURE FOR DIAGNOSIS OF BACTERIAL VS VIRAL INFECTIONS Final Rejection THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
17905784 NOVEL NUCLEIC ACID TEMPLATE STRUCTURE FOR SEQUENCING Final Rejection Roche Sequencing Solutions, Inc.
17422093 A METHOD FOR DETERMINING THE SEVERITY OR GRADE OF HUMAN PAPILLOMAVIRUS (HPV)-INDUCED DYSPLASIA Non-Final OA Charité - Universitätsmedizin Berlin
17434548 ANALYTE DETECTION METHOD Final Rejection IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
17426057 METHODS FOR PREDICTING A VERY LOW BIRTH WEIGHT Non-Final OA Imperial College of Science, Technology and Medicine
17425611 KIT FOR DETECTING MELANOMA Final Rejection Council of Scientific and Industrial Research
18248285 METHODS AND MEANS FOR AMPLIFICATION-BASED QUANTIFICATION OF NUCLEIC ACIDS Non-Final OA Imperial College Innovations Limited
18265367 DNA APTAMERS FOR THE DETECTION OF MONOMERIC CRP Non-Final OA Universiteit Hasselt
17554181 SYSTEMS FOR SAMPLE ANALYSIS Non-Final OA Biomeme, Inc.
17580425 COMPOSITIONS AND METHOD FOR DETECTING HUMAN PARVOVIRUS NUCLEIC ACID AND FOR DETECTING HEPATITIS A VIRUS NUCLEIC ACIDS IN SINGLE-PLEX OR MULTIPLEX ASSAYS Non-Final OA GEN-PROBE INCORPORATED
18278664 METHOD FOR DETERMINING PRIMARY TUMOR SITE Non-Final OA ONCOCROSS CO., LTD.
16898550 METHODS OF FETAL ABNORMALITY DETECTION Non-Final OA Verinata Health, Inc.
18352651 BIOCHIP AND METHOD FOR TRACKING POSTOPERATIVE RECURRENCE STATUS OF PATIENT WITH LUNG ADENOCARCINOMA Non-Final OA MacKay Medical College
18066953 COMPOSITIONS AND METHODS FOR DETECTION OF VARIANTS Final Rejection Twist Bioscience Corporation
18313146 METHODS FOR DETECTION OF NUCLEOTIDE MODIFICATION Non-Final OA BLUECAT IP LIMITED
18031165 MASSIVELY PARALLELED MULTI-PATIENT ASSAY FOR PATHOGENIC INFECTION DIAGNOSIS AND HOST PHYSIOLOGY SURVEILLANCE USING NUCLEIC ACID SEQUENCING Non-Final OA The USA, as represented by the Secretary, Dept. of Health and Human Services

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month